Stephens initiated coverage on Myriad Genetics IncMYGN with an Equal-Weight rating and a price target of $22.
The analyst writes that the company has been at the forefront of genetic testing for decades. However, in recent years, a lack of innovation, operational issues, and competition resulted in below-market growth.
In 2020, MYGN announced a transformation plan to streamline its business and accelerate organic growth to 9% – 12%. Thus far, the transformation has gone well, Stephens note.
Selling prices have stabilized, the OpEx margin has declined, and new products are being developed/launched.
Stephens says MYGN is still in the early growth acceleration phase, thus making the analyst hesitant about the company’s ability to accelerate/sustain elevated growth amid competition and without investments.
Stephens says MUGN shares are cheap. If the stock can accelerate growth into the low double-digits and gain investors’ confidence, even minimal multiple expansion could drive upside to shares.
Price Action: MYGN shares are down 1.97% at $20.41 on the last check Thursday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
